SNSW(SH:688117) 智通财经网·2025-08-14 09:56Core Viewpoint - Shengnuo Bio (688117.SH) reported significant growth in its 2025 semi-annual results, with revenue reaching 338 million yuan, a year-on-year increase of 69.69%, and net profit attributable to shareholders soaring by 308.29% to 88.96 million yuan [1] Financial Performance - The company achieved a revenue of 338 million yuan, reflecting a 69.69% increase compared to the previous year [1] - Net profit attributable to shareholders was 88.96 million yuan, marking a substantial year-on-year growth of 308.29% [1] - The non-recurring net profit was 89.48 million yuan, which represents a remarkable increase of 367.92% year-on-year [1] - Basic earnings per share stood at 0.57 yuan [1] Key Drivers of Growth - The significant increase in net profit was primarily driven by: 1. A substantial rise in overseas sales of raw materials, Semaglutide and Teriparatide, contributing to profit growth [1] 2. A delay in the outsourced project for injectable Acetate Octreotide with Meihua Dingchang, resulting in reduced R&D expenses compared to the previous year [1] 3. A price adjustment in the collection of injectable Octreotide in May 2024, leading to decreased market business expenses [1] 4. A refund of land deposit from the Meishan Finance Bureau in March 2025, which reversed credit impairment losses by 4 million yuan [1]